Experienced in Contact Dermatitis

Taisuke Ito

Shizuoka, JP 
Experienced in Contact Dermatitis
Shizuoka, JP 
OverviewLocationsClinical Research

Overview

Taisuke Ito practices in Shizuoka, Japan. Ito is rated as an Experienced expert by MediFind in the treatment of Contact Dermatitis. Their top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Marie Unna Congenital Hypotrichosis, and Atopic Dermatitis.

Their clinical research consists of co-authoring 121 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Contact Dermatitis.

Locations

Shizuoka, Japan
Other Locations
Hamamatsu, Japan
Kyoto, 6068507, Japan
Tokyo, Japan
PT Medical Center, 4-10-3, Minato, 1060032, Japan
Wakayama, Japan
Niigata, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

121 Total Publications

Immunohistochemical analysis of p53 and LKB1 as predictive biomarkers of immune checkpoint inhibitor response in non-small cell lung cancer.
Immunohistochemical analysis of p53 and LKB1 as predictive biomarkers of immune checkpoint inhibitor response in non-small cell lung cancer.
Journal: Translational lung cancer research
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ito's expertise for a condition
ConditionClose
View All 43 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile